Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Bausch Health Companies Inc., together with its subsidiaries, develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through five segments: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb segment offers products with a focus on the vision care, surgical, and consumer, surgical, and ophthalmic pharmaceuticals products. The Salix segment provides gastroenterology products in the United States. The International Rx segment offers Solta products, branded and generic pharmaceutical products, OTC products, and medical device products, and Bausch + Lomb products in Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. The Ortho Dermatologics segment provides dermatological products in the United States; and Solta medical aesthetic devices internationally. The Diversified Products segment offers pharmaceutical products in the areas of neurology and other therapeutic classes, as well as generic and dentistry products in the United States. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.

Bausch Health Companies Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

EXPANSION IMPROVES ACCESS TO TREATMENT OPTIONS WITHIN PERIODONTAL CARE AND HELPS STRENGTHEN PARTNERSHIPS WITH DENTAL PROFESSIONALS WITHIN THESE POPULATIONS. LAVAL, QC / ACCESS NEWSWIRE / NOVEMBER 5, 2025 / BAUSCH HEALTH COMPANIES INC. (NYSE:BHC)(TSX:BHC), A GLOBAL DIVERSIFIED PHARMACEUTICAL COMPANY, AND ORAPHARMA, ITS DENTAL PRODUCTS BUSINESS, TODAY ANNOUNCED THE COMMERCIAL EXPANSION OF ORAPHARMA INTO CANADA AND PUERTO RICO.

BAUSCH HEALTH'S ORAPHARMA EXPANDS INTO CANADA AND PUERTO RICO, HELPING TO ADDRESS UNMET NEEDS IN PERIODONTAL DISEASE

VAUGHAN, ONTARIO--(BUSINESS WIRE)--BAUSCH + LOMB CORPORATION (NYSE/TSX: BLCO), A LEADING GLOBAL EYE HEALTH COMPANY DEDICATED TO HELPING PEOPLE SEE BETTER TO LIVE BETTER, WILL HOLD AN INVESTOR DAY ON THURSDAY, NOV. 13, 2025, AT THE NEW YORK STOCK EXCHANGE. CHAIRMAN AND CEO BRENT SAUNDERS WILL PROVIDE AN UPDATE ON THE COMPANY'S TRANSFORMATION AND STRATEGIC OUTLOOK, AND EXECUTIVE VICE PRESIDENT AND CHIEF FINANCIAL OFFICER SAM ELDESSOUKY WILL SHARE DETAILS ON A THREE-YEAR PLAN TO DRIVE SUSTAINABLE,.

BAUSCH + LOMB TO HOLD INVESTOR DAY ON NOV. 13

THIRD QUARTER CONSOLIDATED REVENUES OF $2.68 BILLION, UP 7% ON A REPORTED BASIS AND 5% ON AN ORGANIC (NON-GAAP)1 BASIS OVER THE PRIOR YEAR PERIOD GAAP NET INCOME ATTRIBUTABLE TO BAUSCH HEALTH OF $179 MILLION AND GAAP NET INCOME OF $181 MILLION CONSOLIDATED ADJUSTED EBITDA ATTRIBUTABLE TO BAUSCH HEALTH (NON-GAAP)1 OF $986 MILLION, INCLUDING AN $81 MILLION ACQUIRED IN-PROCESS RESEARCH & DEVELOPMENT ("IPR&D") CHARGE, UP 8% ON A REPORTED BASIS OVER THE PRIOR YEAR PERIOD BAUSCH HEALTH EXCLUDING BAUSCH + LOMB THIRD QUARTER 2025 RESULTS DELIVERED TENTH CONSECUTIVE QUARTER OF YEAR-OVER-YEAR REVENUE AND ADJUSTED EBITDA (NON-GAAP)1 GROWTH, WITH 7% REPORTED AND 5% ORGANIC (NON-GAAP)1 REVENUE GROWTH, AND 7% ADJUSTED EBITDA (NON-GAAP)1 GROWTH, INCLUDING AN $81 MILLION CHARGE FOR ACQUIRED IPR&D RAISING FULL-YEAR 2025 REVENUE, ADJUSTED EBITDA (NON-GAAP)1, AND ADJUSTED CASH FLOW FROM OPERATIONS (NON-GAAP)1 GUIDANCE COMPLETED ACQUISITION OF DURECT CORPORATION, EXPANDING BAUSCH HEALTH'S HEPATOLOGY PORTFOLIO WITH ADDITION OF LEAD ASSET, LARSUCOSTEROL, A NOVEL EPIGENETIC MODULATOR WITH FDA BREAKTHROUGH THERAPY DESIGNATION FOR TREATMENT OF ALCOHOL-ASSOCIATED HEPATITIS ("AH") LAVAL, QC / ACCESS NEWSWIRE / OCTOBER 29, 2025 / BAUSCH HEALTH COMPANIES INC. (NYSE:BHC)(TSX:BHC) ("BAUSCH HEALTH" OR THE "COMPANY" OR "WE" OR "OUR") TODAY ANNOUNCED ITS THIRD QUARTER 2025 FINANCIAL RESULTS AND OTHER KEY UPDATES FROM THE QUARTER. "THE THIRD QUARTER MARKS OUR TENTH CONSECUTIVE QUARTER OF YEAR-OVER-YEAR GROWTH IN REVENUE AND ADJUSTED EBITDA FOR BAUSCH HEALTH, EXCLUDING BAUSCH + LOMB, HIGHLIGHTING OUR TEAM'S CONSISTENT EXECUTION AND OPERATIONAL EXCELLENCE.

BAUSCH HEALTH ANNOUNCES THIRD QUARTER 2025 RESULTS

LAVAL, QC / ACCESS NEWSWIRE / OCTOBER 9, 2025 / BAUSCH HEALTH COMPANIES INC. (THE "COMPANY") (NYSE:BHC)(TSX:BHC) TODAY ANNOUNCED THE RESULTS OF THE SPECIAL MEETING OF SHAREHOLDERS HELD ON OCTOBER 7, 2025 (THE "SHAREHOLDERS MEETING"). AT THE SHAREHOLDERS MEETING, SHAREHOLDERS OF THE COMPANY APPROVED THE RATIFICATION, CONFIRMATION AND APPROVAL OF THE ADOPTION OF THE COMPANY'S AMENDED AND RESTATED SHAREHOLDER RIGHTS PLAN AGREEMENT DATED APRIL 14, 2025, AS AMENDED AND RESTATED ON AUGUST 25, 2025 (THE "RIGHTS PLAN AGREEMENT"), AS DESCRIBED IN DETAIL IN THE COMPANY'S MANAGEMENT PROXY CIRCULAR AND PROXY STATEMENT DATED AUGUST 27, 2025.

BAUSCH HEALTH ANNOUNCES RESULTS OF SPECIAL MEETING OF SHAREHOLDERS

THE BALANCING ACT AIRING ON LIFETIME WILL SHOWCASE HOW INNOVATIVE TREATMENTS THERMAGE FLX, CLEAR + BRILLIANT, AND FRAXEL FTX OFFER ENERGY-BASED TREATMENT OPTIONS THAT HELP MAINTAIN A YOUTHFUL APPEARANCE WHILE ENHANCING NATURAL BEAUTY. LAVAL, QC / ACCESS NEWSWIRE / SEPTEMBER 30, 2025 / BAUSCH HEALTH COMPANIES INC. (NYSE:BHC)(TSX:BHC), A GLOBAL, DIVERSIFIED PHARMACEUTICAL COMPANY, AND ITS AESTHETIC BUSINESS, SOLTA MEDICAL, A GLOBAL LEADER IN THE MEDICAL AESTHETICS MARKET, WILL BE FEATURED ON THE BALANCING ACT, AIRING ON LIFETIME, IN A SPECIAL EPISODE SPOTLIGHTING ITS PORTFOLIO OF NON-INVASIVE SKIN REJUVENATION AND TIGHTENING TECHNOLOGIES: THERMAGE FLX, CLEAR + BRILLIANT AND FRAXEL FTX.

BAUSCH HEALTH'S AESTHETIC BUSINESS, SOLTA MEDICAL, BRINGS NON-INVASIVE AESTHETIC INNOVATIONS TO NATIONAL TV

LAVAL, QC / ACCESS NEWSWIRE / SEPTEMBER 30, 2025 / BAUSCH HEALTH COMPANIES INC. (NYSE:BHC)(TSX:BHC) WILL RELEASE THIRD QUARTER 2025 FINANCIAL RESULTS AFTER MARKET CLOSE ON WEDNESDAY, OCTOBER 29, 2025. BAUSCH HEALTH WILL HOST A LIVE CONFERENCE CALL AND WEBCAST AT 5:00 P.M.

BAUSCH HEALTH TO ANNOUNCE THIRD QUARTER 2025 RESULTS ON OCTOBER 29

DESIGNED FOR DENTAL PROFESSIONALS, ORATALKS CONNECTS LEADING VOICES WITH INSIGHTS TO SPARK MEANINGFUL DIALOGUE. NINE-EPISODE INAUGURAL SEASON HOSTED BY INDUSTRY THOUGHT LEADER MELISSA K.

BAUSCH HEALTH'S ORAPHARMA INTRODUCES "ORATALKS," A NEW PODCAST BRINGING BOLD CONVERSATIONS TO DENTISTRY

THE TRANSACTION ADDS LARSUCOSTEROL, AN FDA BREAKTHROUGH THERAPY FOR ALCOHOL-ASSOCIATED HEPATITIS WITH A REGISTRATIONAL PHASE 3 CLINICAL TRIAL IN DEVELOPMENT, TO BAUSCH HEALTH'S HEPATOLOGY PIPELINE LAVAL, QC, AND CUPERTINO, CA / ACCESS NEWSWIRE / SEPTEMBER 11, 2025 / BAUSCH HEALTH COMPANIES INC. (NYSE:BHC)(TSX:BHC) ("BAUSCH HEALTH"), A GLOBAL, DIVERSIFIED PHARMACEUTICAL COMPANY, TODAY ANNOUNCED THE SUCCESSFUL COMPLETION OF ITS PREVIOUSLY ANNOUNCED TENDER OFFER TO ACQUIRE DURECT CORPORATION ("DURECT"). UNDER THE TERMS OF THE AGREEMENT, BAUSCH HEALTH ACQUIRED ALL OUTSTANDING SHARES OF DURECT FOR $1.75 PER SHARE IN CASH, REPRESENTING A TOTAL UPFRONT CASH PAYMENT OF APPROXIMATELY $63 MILLION AT CLOSING.

BAUSCH HEALTH COMPLETES ACQUISITION OF DURECT CORPORATION, EXPANDING LATE-STAGE LIVER DISEASE PORTFOLIO

VAUGHAN, ONTARIO--(BUSINESS WIRE)--BAUSCH + LOMB CORPORATION (NYSE/TSX: BLCO), A LEADING GLOBAL EYE HEALTH COMPANY DEDICATED TO HELPING PEOPLE SEE BETTER TO LIVE BETTER, TODAY ANNOUNCED THAT THE AMERICAN JOURNAL OF OPHTHALMOLOGY HAS PUBLISHED RESULTS OF THE PIVOTAL U.S. CLINICAL TRIAL OF THE ENVISTA ENVY NOVEL FULL VISUAL RANGE INTRAOCULAR LENS. THE STUDY COMPARED VISUAL, REFRACTIVE AND PATIENT-REPORTED OUTCOMES FOLLOWING IMPLANTATION OF ENVISTA ENVY AND THE ENVISTA MONOFOCAL IOL IN CATARACT S.

BAUSCH + LOMB ANNOUNCES PUBLICATION OF ENVISTA ENVY FULL RANGE OF VISION INTRAOCULAR LENS PIVOTAL U.S. CLINICAL TRIAL

VAUGHAN, ONTARIO--(BUSINESS WIRE)--BAUSCH + LOMB CORPORATION (NYSE/TSX: BLCO), A LEADING GLOBAL EYE HEALTH COMPANY DEDICATED TO HELPING PEOPLE SEE BETTER TO LIVE BETTER, TODAY ANNOUNCED CLINICAL OPHTHALMOLOGY HAS PUBLISHED RESULTS FROM AN INVESTIGATOR-INITIATED STUDY WHICH EVALUATED THE EFFECTIVENESS OF XIIDRA (LIFITEGRAST OPHTHALMIC SOLUTION) 5% IN ALLEVIATING END-OF-DAY (EOD) EYE DRYNESS AND DISCOMFORT IN SYMPTOMATIC CONTACT LENS (CL) WEARERS.* XIIDRA IS A PRESCRIPTION EYE DROP USED TO TREAT.

BAUSCH + LOMB ANNOUNCES PUBLICATION OF DATA FROM A PROSPECTIVE STUDY EVALUATING THE EFFICACY OF XIIDRA IN ALLEVIATING DISCOMFORT IN SYMPTOMATIC CONTACT LENS WEARERS

LAVAL, QC / ACCESS NEWSWIRE / SEPTEMBER 5, 2025 / BAUSCH HEALTH COMPANIES INC. (NYSE:BHC)(TSX:BHC), A GLOBAL, DIVERSIFIED PHARMACEUTICAL COMPANY, AND SOLTA MEDICAL, A GLOBAL LEADER IN THE MEDICAL AESTHETICS MARKET, TODAY ANNOUNCED THAT THE COMPANY'S PROVEN THERMAGE TECHNOLOGY HAS SUCCESSFULLY BEEN USED TO PERFORM MORE THAN 5 MILLION SKIN TIGHTENING AND SMOOTHING TREATMENTS. THERMAGE UTILIZES MONOPOLAR RADIOFREQUENCY ENERGY THAT CAN SAFELY HEAT LAYERS OF SKIN AND STIMULATE COLLAGEN PRODUCTION, NATURALLY.

BAUSCH HEALTH'S AESTHETIC BUSINESS, SOLTA MEDICAL, SURPASSES MILESTONE OF 5 MILLION SKIN TIGHTENING TREATMENTS WITH THERMAGE(R) NON-SURGICAL SYSTEM

LAVAL, QC AND CUPERTINO, CA / ACCESS NEWSWIRE / AUGUST 26, 2025 / BAUSCH HEALTH COMPANIES INC. (NYSE:BHC)(TSX:BHC), A GLOBAL, DIVERSIFIED PHARMACEUTICAL COMPANY, AND DURECT CORPORATION (NASDAQ:DRRX) TODAY ANNOUNCED THAT BHC LYON MERGER SUB, INC. ("PURCHASER"), A WHOLLY OWNED SUBSIDIARY OF BAUSCH HEALTH AMERICAS, INC. ("BHA"), AND AN INDIRECT SUBSIDIARY OF BAUSCH HEALTH COMPANIES INC. ("BHC"), HAS EXTENDED THE EXPIRATION DATE OF ITS TENDER OFFER (THE "OFFER") TO ACQUIRE ALL OF THE OUTSTANDING SHARES OF COMMON STOCK OF DURECT CORPORATION FOR $1.75 PER SHARE IN AN ALL-CASH TRANSACTION FOR AN UPFRONT CONSIDERATION OF APPROXIMATELY $63 MILLION AT CLOSING, WITH THE POTENTIAL FOR TWO ADDITIONAL NET SALES MILESTONE PAYMENTS OF UP TO $350 MILLION IN THE AGGREGATE (SUBJECT TO CERTAIN ADJUSTMENTS IN RESPECT OF A RETENTION PLAN) IF THE MILESTONES ARE ACHIEVED BEFORE THE EARLIER OF THE 10 YEAR ANNIVERSARY OF THE FIRST COMMERCIAL SALE OF LARSUCOSTEROL (5-CHOLESTEN-3SS, 25-DIOL 3-SULFATE SODIUM SALT) IN THE UNITED STATES AND DECEMBER 31, 2045. THE OFFER, WHICH WAS PREVIOUSLY SCHEDULED TO EXPIRE AT 5:00 P.M.

BAUSCH HEALTH ANNOUNCES EXTENSION OF DURECT CORPORATION TENDER OFFER TO SEPTEMBER 10, 2025

LAVAL, QC / ACCESS NEWSWIRE / AUGUST 21, 2025 / BAUSCH HEALTH, CANADA INC., PART OF BAUSCH HEALTH COMPANIES INC. (NYSE:BHC)(TSX:BHC), A GLOBAL, DIVERSIFIED PHARMACEUTICAL COMPANY, TODAY ANNOUNCED THAT PRCABTREO (CLINDAMYCIN PHOSPHATE, ADAPALENE AND BENZOYL PEROXIDE) GEL 1.2% W/W, 0.15% W/W AND 3.1% W/W, FOR THE TREATMENT OF ACNE VULGARIS,1 IS NOW AVAILABLE TO BENEFICIARIES OF THE PUBLIC DRUG PLANS OF QUEBEC AND SASKATCHEWAN. THIS NEW PUBLIC DRUG PLAN AVAILABILITY OF CABTREO IS IN ADDITION TO THAT ANNOUNCED LAST MONTH FOR THOSE USING THE ONTARIO AND NOVA SCOTIA PUBLIC DRUG PLANS AS WELL AS THROUGH THE FEDERAL GOVERNMENT'S NON-INSURED HEALTH BENEFITS (NIHB) DRUG PLAN FOR INDIGENOUS POPULATIONS AS WELL AS THOSE OF THE CORRECTIONAL SERVICE OF CANADA (CSC) AND VETERANS AFFAIRS CANADA.

BAUSCH HEALTH, CANADA INC. TREATMENT FOR ACNE VULGARIS, (PR)CABTREO(TM) (CLINDAMYCIN PHOSPHATE, ADAPALENE AND BENZOYL PEROXIDE GEL), NOW AVAILABLE THROUGH PUBLIC DRUG PLANS OF QUEBEC AND SASKATCHEWAN

Bausch Health Companies Inc.

BHC

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Bausch Health Companies Inc.

BHC.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

BHC